The Vagus Nerve in Parkinson’s Disease: From Braak Hypothesis to Treatment

Parkinson’s disease (PD) has traditionally been understood as a brain disorder — the progressive loss of dopaminergic neurons in the substantia nigra. But over the past two decades, a body of evidence has emerged suggesting that the disease may begin not in the brain but in the gut, and that the vagus nerve is the physical highway along which it travels. This gut-to-brain hypothesis, most associated with Heiko Braak’s staging model, has reshaped how researchers think about PD’s origins and opened new avenues for early detection and potential prevention.

The Braak Staging Hypothesis

In 2003, Heiko Braak and colleagues published a staging system for Parkinson’s based on the distribution of alpha-synuclein — the misfolded protein that forms Lewy bodies, the pathological hallmark of PD. Braak’s key observation was that alpha-synuclein pathology appears in a predictable ascending sequence: it shows up first in the olfactory bulb and the dorsal motor nucleus of the vagus (DMV) in the brainstem, then climbs through the pons, midbrain, and eventually into the cortex.

The DMV is where the vagus nerve’s motor fibres originate before descending to innervate the gut, heart, and lungs. Its involvement at Braak Stage 1 — before substantia nigra damage and before motor symptoms appear — suggested that the pathological process might start peripherally and ascend via the vagus nerve to reach the brain.

Braak extended this logic to propose that alpha-synuclein pathology might originate in the enteric nervous system (the gut’s own network of neurons) and propagate retrogradely along vagal afferents to the DMV, from there spreading rostrally through connected brainstem nuclei. This “dual-hit” hypothesis — with simultaneous initiation in the olfactory bulb and the gut — offered an explanation for why loss of smell (hyposmia) and constipation both precede motor symptoms by a decade or more in most PD patients.

Evidence From Vagotomy Studies

If the vagus nerve is the conduit for gut-to-brain alpha-synuclein spread, then severing it should reduce PD risk. This prediction was testable because truncal vagotomy — cutting the main vagal trunks — was a common surgical treatment for peptic ulcer disease before proton pump inhibitors replaced it in the 1980s and 1990s.

In 2015, Svensson and colleagues published a landmark Danish registry study following over 15,000 vagotomy patients over decades. They found that truncal vagotomy was associated with a roughly 40-50% reduced risk of developing Parkinson’s disease, but only after a lag period of more than five years — consistent with a slow propagation process. Critically, selective vagotomy (which cuts only smaller branches near the stomach while preserving the vagal trunks) did not reduce PD risk, supporting the specific role of the main vagal conduit.

A 2017 Swedish registry study by Liu and colleagues found a similar trend, though the association was weaker and did not reach statistical significance after full adjustment. A 2019 Korean study by Kim and colleagues confirmed the protective association of truncal vagotomy with a large cohort. The collective evidence is suggestive but not conclusive — registry studies cannot prove causation, and the vagotomy population is biased toward peptic ulcer patients who differ from the general population in other ways.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

Alpha-Synuclein Seeding: Animal Evidence

Direct experimental evidence comes from animal models. In 2019, Kim and colleagues published a pivotal study in Neuron demonstrating that injection of pathological alpha-synuclein fibrils into the gut wall of mice led to spread of alpha-synuclein pathology along the vagus nerve to the DMV and eventually to the substantia nigra, producing dopaminergic neuron loss and motor deficits. Crucially, truncal vagotomy before the injection blocked this brain-directed spread completely.

This prion-like propagation — where misfolded alpha-synuclein acts as a seed that templates the misfolding of normal alpha-synuclein in connected neurons — parallels the transmission mechanism seen in prion diseases. The vagus nerve, with its direct gut-to-brainstem neural pathway, provides an anatomical corridor for this cell-to-cell spread that bypasses the blood-brain barrier entirely.

Earlier work by Holmqvist and colleagues (2014, Acta Neuropathologica) had shown similar vagal transport of alpha-synuclein in rats, and Ulusoy and colleagues (2013) demonstrated that viral-mediated overexpression of alpha-synuclein in the DMV led to caudo-rostral spread into connected brain regions.

The Gut Microbiome Connection

The gut-origin hypothesis intersects with the now-extensive literature on gut microbiome alterations in PD. Scheperjans and colleagues (2015, Movement Disorders) first reported that PD patients have a distinct gut microbiome composition compared with healthy controls, with notably reduced abundance of Prevotellaceae — a bacterial family associated with gut barrier integrity and short-chain fatty acid production.

Subsequent studies have confirmed widespread microbiome dysbiosis in PD, including increased abundance of Enterobacteriaceae (which correlates with motor severity) and altered short-chain fatty acid profiles. Sampson and colleagues (2016, Cell) demonstrated that transplanting the gut microbiome from PD patients into germ-free mice produced motor deficits and neuroinflammation, while microbiome transplant from healthy controls did not.

The vagus nerve is the primary communication channel between gut bacteria and the brain. Microbial metabolites can activate vagal afferent terminals in the gut wall, and changes in microbial composition may alter the local inflammatory environment enough to trigger or accelerate alpha-synuclein misfolding in enteric neurons. Whether microbiome interventions (probiotics, faecal transplantation, dietary change) can modulate PD risk or progression via this vagal pathway is an active area of investigation — early-phase clinical trials of faecal microbiota transplantation in PD are underway as of 2025.

Constipation as a Prodromal Signal

If PD begins in the gut, then gastrointestinal dysfunction should precede motor symptoms — and it does. Constipation is one of the strongest prodromal markers for PD, appearing on average 10-20 years before tremor or rigidity. The Honolulu-Asia Aging Study found that men with fewer than one bowel movement per day had a roughly 2.7-fold increased risk of developing PD over 20 years.

This early GI dysfunction is consistent with alpha-synuclein pathology in the enteric nervous system disrupting normal colonic motility years before the ascending pathology reaches the substantia nigra. Alpha-synuclein inclusions have been identified in colonic biopsies of PD patients and even in some individuals with constipation who have not yet developed motor PD, though the diagnostic sensitivity and specificity of enteric alpha-synuclein detection remain insufficient for clinical screening.

VNS as a Potential PD Treatment

Vagus nerve stimulation is being explored as a therapeutic intervention for PD, distinct from its role in the disease’s pathogenesis. The rationale is that VNS-driven activation of the NTS and locus coeruleus may reduce neuroinflammation, enhance neuroplasticity, and potentially modulate dopaminergic circuits.

A 2021 pilot study by Mondal and colleagues found that non-invasive cervical VNS (gammaCore device) improved gait freezing and upper-limb function in a small group of PD patients over four weeks. A 2022 study by Morris and colleagues reported that taVNS (ear-based stimulation) improved both motor and non-motor symptoms including sleep quality and mood in a randomised crossover design.

These results are preliminary. The sample sizes are small (typically 10-30 participants), follow-up periods are short, and the optimal stimulation parameters for PD are unknown. Whether VNS can slow disease progression — as opposed to temporarily improving symptoms — has not been tested. Several larger trials are now recruiting, and the answer will depend on whether vagal afferent activation can meaningfully reduce the neuroinflammatory and neurodegenerative processes driving PD progression.

Implications and Limitations

The vagal-PD hypothesis is compelling but not universal. An estimated 10-30% of PD cases do not follow the Braak staging pattern — some show cortical pathology without early brainstem involvement, and familial PD cases (particularly those with LRRK2 or GBA mutations) may follow different pathological sequences. PD is likely a syndrome with multiple initiating mechanisms, of which gut-to-brain vagal propagation is one — possibly the most common, but not the only one.

The practical implications are still developing. Truncal vagotomy is not a viable preventive intervention (it was abandoned as ulcer treatment for good reason — it causes significant GI side effects). But the gut-origin model is redirecting PD research toward earlier detection through GI biomarkers, microbiome-targeted interventions, and potentially alpha-synuclein immunotherapies that could intercept the pathological process before it reaches the brain.

Want to understand how the vagus nerve connects your gut, brain, and nervous system in health and disease? Get My Vagus Nerve & Me eBook for the complete picture.